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OBJECTIVES The goal of this research was to study the effect of locally delivered 17-estradiol (17-E)
during angioplasty on endothelial function after percutaneous transluminal coronary angio-
plasty (PTCA) at four weeks.
BACKGROUND The endothelium plays a major role in the structural and functional integrity of coronary
arteries and is damaged by PTCA.
METHODS Juvenile swine were subjected to PTCA, after which each artery was randomly-assigned to
600-g 17-E delivered locally, an equal volume of vehicle (V) or PTCA alone. After four
weeks, the improvement in endothelial function was assessed by angiography using intra-
coronary acetylcholine (Ach) infusion and by immunohistochemistry.
RESULTS At 105 mol/l and 104 mol/l Ach, significant vasoconstriction was noted in arteries treated
with PTCA alone (p  0.01 and p  0.0001, respectively) and with PTCA plus V (p  0.02
and p  0.001, respectively). No significant vasoconstrictive response to Ach was observed in
arteries treated with PTCA plus 17-E. Immunohistochemistry of vessels four weeks after
PTCA revealed enhanced re-endothelialization (p  0.0005) and endothelial nitric-oxide
synthase (eNOS) expression (p  0.0005) in PTCA plus 17-E-treated arteries compared
with the other two treatment groups. Arteries treated with 17-E showed significantly lower
neointima formation, which correlated inversely with the extent of re-endothelialization and
eNOS expression.
CONCLUSIONS Locally delivered 17-E significantly enhances re-endothelialization and endothelial function
after PTCA, possibly by improving the expression of eNOS. Since endothelial dysfunction
can promote both restenosis and coronary spasm, local 17-E administration is a promising
new approach to improve long-term results after PTCA. (J Am Coll Cardiol 2001;38:
1570–6) © 2001 by the American College of Cardiology
The vital role of the endothelium in the regulation of
vascular tone is well recognized (1). The endothelium also
has important inhibitory effects on platelet aggregation,
monocyte adhesion and vascular smooth muscle cell (SMC)
proliferation (2). Endothelial injury, with consequent endo-
thelial dysfunction, is caused by percutaneous transluminal
coronary angioplasty (PTCA) (3) and may play an impor-
tant role in subsequent restenosis (4). Endothelial function
worsens progressively after balloon injury of porcine coro-
nary arteries (5). Prolonged systemically administered 17-
estradiol (17-E) accelerates endothelial recovery in vivo
after arterial injury (6). Since endothelial injury due to
PTCA is a local event, we hypothesized that local delivery
of a single dose of 17-E after PTCA may enhance
endothelial recovery.
METHODS
Animal preparation and handling. The committee ap-
proved the study protocol for ethical animal research of the
Montreal Heart Institute. Eleven juvenile farm pigs (three
immature females with intact ovaries and eight castrated
males) weighing 20 to 25 kg were utilized as previously
described (7).
Procedure. Using a standard PTCA balloon-catheter (bal-
loon/artery ratio 1.1 to 1.2:1), three successive 30-s infla-
tions at 10 atm were made with 30-s intervals between
inflations. The location of each PTCA was the proximal to
midportion of the left anterior descending coronary artery
(LAD), left circumflex coronary artery and right coronary
artery (RCA). For local delivery, the InfusaSleeve catheter
(LocalMed Inc.) was used. Each coronary artery was ran-
domized to receive 600 g 17-E (in 5 ml), vehicle (V)
alone (5 ml) or PTCA alone. The vessel location was LAD
(3, 4, 4), left circumflex coronary artery (4, 2, 5), RCA (4,
5, 2) in the 17-E, PTCA plus V or PTCA alone arm,
respectively. In the last two animals, only two arteries were
randomized to treatment with either PTCA plus 17-E or
PTCA alone; each uninjured (naive) coronary artery was
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utilized to assess response to acetylcholine (Ach) and
immunohistochemistry of normal porcine coronary arteries.
Intracoronary Ach infusion. All 11 animals underwent
cardiac catheterization four weeks after PTCA. After a
baseline coronary angiogram, selective cannulation of the
proximal portion of a coronary artery was performed with a
single-lumen balloon catheter (TotalCross, Schneider,
Minneapolis, Minnesota) for administration of vasoactive
agents. Acetylcholine (107 mol/l, 106 mol/l, 105 mol/l
and 104 mol/l) was infused for 3 min each at 1 ml/min (to
achieve estimated coronary artery blood concentrations of
109 mol/l, 108 mol/l, 107 mol/l and 106 mol/l,
respectively [8]) through the lumen-port of the catheter.
Coronary angiography was performed after each dose.
Immediately after infusion of the highest concentration of
Ach and angiography, 100 g of nitroglycerin was admin-
istered via the lumen-port of the catheter, and a coronary
angiogram was performed. The same protocol was repeated
for the other two coronary arteries.
Quantitative coronary angiography. Coronary angiogra-
phy was performed as previously reported (7) with a
single-plane imaging system (Electromed, St-Eustache,
Que´bec). An independent observer blinded to the
treatment-assignment of vessels performed each segment
measurement in three consecutive end-diastolic frames, and
the results were averaged.
Immunohistochemistry. The animals were euthanized at
four weeks as previously described (7). From the injured
segments and the two naive arteries, serial sections of 3 to
5 mm were made. The sections were then treated with
incremental concentrations of alcohol, followed by xylene
and paraffin. Slices of 6 m thickness were prepared and
stained with Verhoeff’s stain for morphometry. A minimum
of three slices for each artery was analyzed by morphometry,
and the results were averaged. The areas of: 1) external
elastic lamina; 2) internal elastic lamina; and 3) lumen were
measured by digital planimetry, and the neointimal area
([2]  [3]) and media area ([1]  [2]) were obtained. The
morphologic percentage of stenosis was calculated as 100
(1  [3]/[2]).
Immunohistochemical analyses were performed on cross
sections of arteries. For each artery, two sections obtained
from the region demonstrating the maximal neointimal
response (as observed on morphometry) were analyzed and
the results averaged. The lumen circumference and the
sum-total of the luminal border staining positively were
measured for each section. The percentage of re-
endothelialization and the percentage of endothelial nitric
oxide synthase (eNOS) expression were calculated as per-
centages of the lumen circumference of the cross section
staining positively by analysis with the lectin Dolichos biflorus
agglutinin and eNOS stains, respectively. Immunohisto-
chemical measurements were made under high-power
(1,000) by an examiner blinded to the treatment groups
with appropriate positive and negative controls. For lectin
immunohistochemistry, the 6 m slices were first treated
with hydrogen peroxide and methanol to block endogenous
peroxide, incubated with the Dolichos biflorus agglutinin
(Sigma, Oakville, Ontario), followed by treatment with
3,3-diaminobenzidine (Vector Laboratories, Burlingame,
California) and counterstaining with hematoxylin. For
eNOS analysis, after blocking of endogenous peroxide and
nonspecific antibodies, the slices were treated serially with
the primary mouse anti-eNOS antibody (Bio/Can Scien-
tific, Mississauga, Ontario), the secondary goat anti-mouse
antibody (Vector Laboratories), incubated with avidin-
biotin (Vector Laboratories), treated with 3,3-
diaminobenzidine (Vector Laboratories) and, finally, coun-
terstained with hematoxylin.
Statistical analysis. The primary analysis end point was
the endothelial function assessed by quantitative coronary
angiography (QCA) after Ach infusion. Values are ex-
pressed as mean  SEM. Basal and post-nitroglycerin
coronary-artery diameters were compared among the three
treatment groups with one-way analysis of variance. For
each treatment group, Bonferroni-corrected two-tailed t
tests were used for comparisons between the basal coronary
artery diameter and diameter at the end of each Ach
infusion and after nitroglycerin. The Kruskal-Wallis test
was used for comparison of morphometry, lectin and eNOS
expression among the three treatment groups. The linearity
of relationships between variables was analyzed with Pear-
son correlation coefficients. Values were considered signifi-
cant if p 0.05.
RESULTS
There were no significant differences in basal coronary-
artery diameter (2.45  0.18 mm for PTCA plus 17-E;
2.75  0.10 mm for PTCA alone and 2.77  0.15 mm for
PTCA plus V, p  0.4) among the three treatment groups.
No significant differences in vessel distribution between
each treatment arm was observed.
No changes in heart rate, electrocardiogram or blood
pressure were noted during local delivery or during intra-
coronary infusion of vasoactive agents except during the
infusion of 104 mol/l Ach in three arteries (two in the
PTCA alone group and one in the PTCA plus V group)
with a strong vasoconstrictive response associated with
Abbreviations and Acronyms
Ach  acetylcholine
eNOS  endothelial nitric oxide synthase
LAD  left anterior descending artery
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiography
RCA  right coronary artery
SMC  smooth muscle cell
TNF-  tumor necrosis factor-
V  vehicle
17-E  17-estradiol
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ST-segment elevation. Although the ST-segment elevation
and vasospasm were immediately relieved after administra-
tion of nitroglycerin, these three measurements were ex-
cluded from the QCA analysis.
Response of the PTCA alone group to Ach. Compared
with the basal coronary artery diameter (2.75  0.1 mm),
there were no significant changes in coronary artery diam-
eter after intracoronary infusion of 107 mol/l (2.63 
0.1 mm, p 0.4) and 106 mol/l (2.63 0.1 mm, p 0.4)
Ach. At 105 mol/l and 104 mol/l, significant vasocon-
strictive responses were noted (2.3  0.12 mm, p  0.01
and 1.79  0.16 mm, p  0.0001, Figs. 1 and 2). After
nitroglycerin, coronary artery diameter increased from
1.79  0.16 mm after 104 mol/l Ach to 2.45  0.15 mm
(p  0.01 vs. 104 mol/l Ach; p  0.1 vs. basal diameter).
Response of the PTCA plus V group to Ach. Compared
with the basal coronary artery diameter (2.77  0.15 mm),
107 mol/l Ach did not change coronary artery diameter
(2.60  0.13 mm, p  0.4). A trend towards significant
vasoconstriction was noted with 106 mol/l Ach (2.33 
0.16 mm, p  0.06). Significant vasoconstriction was
produced by 105 mol/l (2.24 0.15 mm, p 0.02) and at
104 mol/l (1.89  0.16 mm, p  0.001) Ach infusion,
respectively. Nitroglycerin reversed the vasoconstriction
Figure 1. Representative coronary angiograms demonstrating the vasoconstrictive response to intracoronary infusion of acetylcholine (Ach) 104 mol/l
obtained from the same animal. Column A  basal, column B  post-Ach, column C  after nitroglycerin. Top  percutaneous transluminal coronary
angioplasty (PTCA) plus vehicle, Middle  PTCA alone, Lower  PTCA plus 17-estradiol groups, respectively. Arrows  PTCA sites.
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(from 1.89  0.16 mm after 104 mol/l Ach to 2.69 
0.16 mm after nitroglycerin [p  0.004 vs. 104 mol/l Ach;
p  0.7 vs. basal diameter]).
Response of PTCA plus 17-E group to Ach. In the
vessels treated with local delivery of 17-E, no significant
vasoconstrictive response to Ach (2.45  0.18 mm under
basal conditions, 2.39 0.17 mm, 2.33 0.17 mm, 2.30
0.17 mm, 2.24  0.17 mm after 107 mol/l, 106 mol/l,
105 mol/l and 104 mol/l Ach infusion, respectively [with
corresponding p values of 0.8, 0.6, 0.6 and 0.4, respectively])
occurred at any concentration. A mild vasodilation was
observed after administration of nitroglycerin: from 2.24 
0.17 mm after 104 mol/l Ach to 2.50  0.16 mm after
nitroglycerin (p  0.4; p  0.9 for after nitroglycerin vs.
basal diameter).
There were no significant differences in the final
coronary-artery diameter achieved after administration of
nitroglycerin among the three groups.
Immunohistochemistry. Immunohistochemical analyses
were performed on all 11 animals. Three arterial segments
were lost/damaged during harvesting of samples (two from
the PTCA alone group, one from the PTCA plus V group).
Re-endothelialization, assessed by the lectin Dolichos biflorus
agglutinin stain (Fig. 3A) was greater in vessels treated with
PTCA plus 17-E compared with the other two groups
(89.8  1.6% for PTCA plus 17-E, 69.3  2.3% for
PTCA alone and 72.8  1.7% for PTCA plus V, p 
0.0005). Endothelial nitric oxide synthase expression (Fig.
3B) was higher in vessels treated with 17-E (36.5  3.2%
for PTCA plus 17-E, 10.1  1.7% for PTCA alone and
9.2  1.4% for PTCA plus V, p  0.0005).
Significant inverse correlations between the extent of
re-endothelialization (r  0.45, p  0.02) and between
eNOS expression (r0.65, p 0.0005) and the response
to Ach were observed (date not shown).
Response of naive coronary arteries. To confirm that the
abnormalities in Ach response, re-endothelialization and
eNOS expression in post-PTCA vessels were due to PTCA
and not simply a consequence of tissue handling or other
technical factors, we studied these variables in two naive
coronary arteries. No vasoconstrictive response was seen
(basal diameter 2.92  0.05 mm) in response to Ach at
106, 105 and 104 mol/l (2.99  0.02 mm, 3.02 
0.02 mm, 3.04  0.04 mm, respectively, p  NS). Immu-
nohistochemical analysis revealed 100% lectin expression
and 57.6  5.2% eNOS expression.
Morphometry. The extent of morphologic tissue injury (9)
induced by the initial angioplasty was similar among the
three groups. Arteries treated with PTCA plus 17-E
demonstrated a significantly smaller neointimal response to
Figure 2. Graph showing the response of the three treatment groups to acetylcholine (Ach). Comparison for each treatment group is made between the
basal coronary-artery diameter and diameter at the end of 107 mol/l, 106 mol/l, 105 mol/l and 104 mol/l Ach, respectively. Nitro  nitroglycerin;
PTCA  percutaneous transluminal coronary angioplasty. *p  0.01; **p  0.0001; ***p  0.02; ****p  0.001.
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injury compared with the other two treatment groups.
Neointimal area (0.49 0.1 mm2 for PTCA plus 17-E vs.
1.04  0.22 mm2 for PTCA alone vs. 1.31  0.38 mm2 for
PTCA plus V, p  0.05), neointimal/media area (0.75 
0.16 vs. 2.17  0.49 vs. 1.97  0.47, p  0.01) and
percentage of morphologic stenosis (18.7  4% vs. 37.3 
7.6% vs. 32.2  6.3%, p  0.05) were lower in PTCA plus
17-E arteries.
DISCUSSION
This study demonstrates for the first time that local delivery
of 17-E immediately after PTCA enhances subsequent
re-endothelialization, eNOS expression and endothelial
function at the site of injury. Besides its critical role in the
regulation of vascular tone, the normal endothelium func-
tions as a barrier between blood elements and underlying
Figure 3. Immunohistochemistry for re-endothelialization (A) and endothelial nitric oxide synthase (eNOS) expression (B) from a representative animal.
Top (40): (a) percutaneous transluminal coronary angioplasty (PTCA) plus 17-estradiol, (b) PTCA alone and (c) PTCA plus vehicle. Lower: portions
of the cross sections are shown under high-power (1,000, d to f, respectively) to highlight positive-staining luminal border. The length of positive staining
in the high-power image is indicated by “RE” and “EN” immediately above each image, with the total luminal length in the image (T) shown above. This
analysis was applied to the entire luminal surface, with percentage of re-endothelialization (RE) calculated as RE/T, where RE and T are the sums
of re-endothelialized segment and total luminal lengths in each image. The extent of re-endothelialization for the cross section is greater in (a) (90%) than
it is in (b) (65.8%) and (c) (66.1). Similar analysis was performed for percentage of eNOS expression (EN).
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vascular SMC. Endothelium-derived NO, a potent vasodi-
lator, also inhibits monocyte adherence and platelet aggre-
gation and adhesion (10) and inhibits vascular SMC migra-
tion (11) and proliferation (12).
Endothelium regeneration and dysfunction after PTCA.
After experimental arterial injury, re-endothelialization
rates of 81% (13) and 50% (14) have been observed. In a
study of specimens of restenotic lesions obtained by atherec-
tomy in humans, no endothelial cells could be demonstrated
(15). Coronary artery spasm due to endothelial dysfunction
has been demonstrated at the site of PTCA (3). Patients
with unstable angina due to restenosis experience signifi-
cantly less recurrent angina upon treatment with intrave-
nous nitroglycerin and no benefit with intravenous heparin,
suggesting abnormal vasoconstriction at the site of PTCA
(16). This phenomenon of abnormal vasoconstriction was
also observed in our experiments (upon provocation with
Ach) in arteries treated with PTCA alone or PTCA plus V;
these changes resolved immediately upon administration of
the endothelium-independent vasodilator nitroglycerin.
Effects of 17-E on the endothelium. Therapy with
subcutaneously implanted 17-E pellets has been reported
to enhance re-endothelialization after arterial injury (6). In
this study, local treatment with a single dose of 17-E at the
time of PTCA was followed by nearly complete re-
endothelialization (89.8  1.6%), significantly greater than
that observed in the groups not treated with 17-E. The
ability of 17-E to increase vascular endothelial growth
factor synthesis (17) and its effect on basic fibroblast growth
factor may be responsible for the enhanced re-
endothelialization (18). In cell culture assay, 17-E treat-
ment resulted in a 50% decrease in apoptosis of human
umbilical-vein endothelial cells exposed to tumor necrosis
factor- (TNF-) (19). Of note, increased TNF- expres-
sion is known to occur after balloon injury (20). The effect
of 17-E to upregulate eNOS expression that we observed
may be responsible for beneficial effects on endothelial
function, as the vascular response to Ach is closely related to
eNOS expression (21). In support of this notion, a strong
inverse relationship was seen in our study between the
vasoconstrictive response to Ach and eNOS expression.
Estrogen has been observed to induce NOS (22,23).
The observations from the immunohistochemical analysis
of the naive and the injured coronary arteries indicate that
impaired re-endothelialization and downregulation of
eNOS expression are evident four weeks after PTCA and
are significantly improved by local delivery of 17-E at the
time of the initial procedure.
A unifying hypothesis for the responses we observed is
that PTCA is associated with endothelial damage and
eNOS downregulation, which prevents the vasodilatory
response to Ach mediated by endothelial NO production.
By improving eNOS expression, 17-E allows the
endothelium-dependent vasodilatory response of Ach to
counteract its direct vasoconstricting action, thus preventing
Ach-induced vasoconstriction at the site of local injury. The
vasodilation by nitroglycerin in Ach-constricted arteries that
had been subjected to PTCA alone is consistent with this
concept, since exogenous nitroglycerin (a NO donor) simply
provides a local NO-related dilation that the eNOS-
deficient angioplastied segment cannot provide for itself.
Endothelial dysfunction and restenosis. In a small obser-
vational study, the majority of patients with documented
spasm at the site of PTCA subsequently developed resten-
osis (24). Recently, endothelial dysfunction at the site of
balloon angioplasty has been demonstrated as an indepen-
dent factor for the development of restenosis (25). In this
study, we demonstrated that enhanced endothelial recovery
after a single dose of locally-delivered 17-E is associated
with significantly reduced neointima formation. Neointima
formation correlated inversely with the extent of re-
endothelialization and eNOS expression (data not shown),
supporting the notion that estrogen-induced endothelial
protection suppressed neointima formation.
Both rapid nongenomic and genomic effects have been
postulated in the influence of 17-E on coronary vascula-
ture (26,27). Although protein synthesis was not quantified
in this study, the enhanced eNOS expression and the
response to Ach observed as late as 28 days after a single
dose of 17-E are consistent with a genomic effect. This is
the first study to suggest a genomic effect after local 17-E
therapy of coronary arteries in vivo.
Study limitations. Spillover of 17-E into systemic circu-
lation could have occurred during local delivery. However,
for systemic 17-E to be effective, therapy for at least two
weeks (with treatment beginning one week before arterial
injury) is required (6), as the 17-E that enters the
circulation is rapidly metabolized (28). Even assuming that
estrogen spillover could exert a systemic effect, all three
treatment arms were applied in each animal so that 17-E
spillover should have occurred equally for all vessels sub-
jected to PTCA. Systemic effects of 17-E would, if
anything, provide equal protection to all vessels. The dif-
ferences noted between the arteries treated with PTCA plus
17-E compared with PTCA alone and PTCA plus V
cannot, therefore, be attributed to such systemic effects. The
relation between the infusion rate of 1 ml/min of Ach and
final estimated concentration in the coronary vascular bed
was derived for the LAD artery (8) and may vary for the
other two coronary arteries. Interarterial variations in coro-
nary flow are unlikely to have had a significant bearing on
the results of the study, as the three treatment groups were
randomly assigned to include an equal representation of the
different coronary arteries. In addition, immunohistochem-
ical evaluation clearly established a significant beneficial
effect on re-endothelialization and eNOS expression in
17-E-treated arteries compared with the other two treat-
ment groups and was not subject to artifacts related to
assumptions about coronary flow. As the female pigs were
prepubertal and the male pigs were castrated, it may not be
appropriate to make generalizations about a gender effect
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from the data obtained. The effects of 17-E may be
reduced with higher levels of testosterone or in subjects with
aging-related endothelial dysfunction. Finally, stents have
become widely used, but evaluating endothelial function in
a stented vessel remains limited and cannot be extrapolated
from our results.
We conclude that a single dose of 17-E delivered locally
after balloon injury can significantly improve re-
endothelialization and enhance endothelial function at the
injured site as late as one month after PTCA. Besides the
beneficial vascular effects of improved endothelial function,
this observation may be of additional importance because
endothelial dysfunction is an independent predictor of
restenosis (25). Improved endothelial function correlated
significantly with decreased neointima formation in
estrogen-treated vessels. The approach of local 17-E
administration during PTCA merits further study, with a
view to potential clinical value in the prevention of vascular
dysfunction and restenosis.
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